not losing weight on compounded semaglutide Compound Embody | Personalized GLP-1 Weight

Our study indicates that GLP1R LoF mutants, in particular those with impaired GLP1R cell surface expression or cAMP activation, are linked to defective insulin secretion in vitro and to impaired glucose homeostasis and adiposity of patients in the 200K participants of the UK Biobank

It should not replace semaglutide, liraglutide, tirzepatide or any treatment prescribed by a clinician

Moreover, for people already dealing with substance abuse, it decreased adverse events and the risk of death by 50%.[ref] Which GLP-1 Agonists are Approved for Weight Loss

This is not a failure of the medicationit reflects the chronic nature of the metabolic pathways these drugs influence